Algert Global LLC Rhythm Pharmaceuticals, Inc. Transaction History

Algert Global LLC

$4.77 Billion
Q2 2025

A detailed history of Algert Global LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Algert Global LLC holds 60,219 shares of RYTM stock, worth $6.45 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

60,219

Previous 61,461 2.02%

Holding current value

$6.45 Million

Previous $3.26 Million 16.86%

% of portfolio

0.08%

Previous 0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$46.95 - $68.11 $58,311 - $84,592	-1,242 Reduced 2.02%	60,219 $3.81 Million
Q1 2025 May 13, 2025	BUY	$48.56 - $61.02 $966,829 - $1.21 Million	19,910 Added 47.92%	61,461 $3.26 Million
Q4 2024 Feb 14, 2025	SELL	$46.91 - $67.33 $592,004 - $849,704	-12,620 Reduced 23.3%	41,551 $2.33 Million
Q3 2024 Nov 12, 2024	SELL	$40.81 - $55.0 $2.04 Million - $2.75 Million	-49,961 Reduced 47.98%	54,171 $2.84 Million
Q2 2024 Aug 14, 2024	BUY	$35.41 - $44.37 $1.24 Million - $1.56 Million	35,084 Added 50.81%	104,132 $4.28 Million
Q1 2024 May 14, 2024	BUY	$39.12 - $52.44 $1.57 Million - $2.11 Million	40,245 Added 139.73%	69,048 $2.99 Million
Q4 2023 Feb 14, 2024	SELL	$21.39 - $49.64 $98,607 - $228,840	-4,610 Reduced 13.8%	28,803 $1.32 Million
Q3 2023 Nov 13, 2023	SELL	$15.81 - $27.8 $406,000 - $713,904	-25,680 Reduced 43.46%	33,413 $766,000
Q2 2023 Aug 14, 2023	BUY	$16.32 - $21.15 $964,397 - $1.25 Million	59,093 New	59,093 $974,000
Q1 2021 May 14, 2021	SELL	$20.25 - $39.49 $244,620 - $477,039	-12,080 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$21.17 - $32.61 $255,733 - $393,928	12,080 New	12,080 $359,000

Others Institutions Holding RYTM

# of Institutions

251

Shares Held

63.9M

Call Options Held

210K

Put Options Held

575K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $5.97B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Rhythm Pharmaceuticals, Inc. Transaction History